The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Projected To Become By 2030 Based On Its 2026 Valuation?
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has experienced swift expansion recently. It will grow from $39.69 billion in 2025 to $45.88 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. Historically, this expansion is attributable to covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $82.61 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This anticipated growth during the forecast period stems from factors such as the rise of personalized cancer vaccines, the expansion of infectious disease development pipelines, swifter platform-based approval processes, increased funding in biotechnology, and the more extensive application of therapeutic vaccines. Key developments expected during this period involve self-amplifying mRNA platforms, enhanced lipid nanoparticle delivery, the implementation of modular vaccine platform designs, swift adaptation to pathogen targets, and the development of next-generation adjuvant systems.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp
What Drivers Are Expected To Influence The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market During The Forecast Period?
The burgeoning need for personalized medicine is anticipated to fuel the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market moving ahead. Personalized medicine represents a healthcare strategy where methods for preventing and treating diseases are customized according to an individual’s genetic makeup, molecular traits, and particular health circumstances. The escalating requirement for personalized medicine stems from the increasing occurrence of intricate and long-term illnesses, given that these conditions necessitate precise and individual-focused therapeutic approaches to enhance the effectiveness and safety of treatments. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for the quick, adaptable, and highly specialized creation of vaccines and therapies, which can be adapted to specific genetic and disease profiles, thereby aiding in the provision of precision healthcare. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA sanctioned 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the growing need for personalized medicine is propelling the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.
What Segment Groups Are Identified Within The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –
1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types
2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies
3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications
4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics
Subsegments:
1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines
2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines
3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines
4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines
5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines
6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines
What Trends Are Advancing Progress In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
Leading companies within the mRNA and next-generation vaccine platforms market are concentrating on developing advanced mRNA-based COVID-19 vaccines. This focus aims to boost immune endurance, widen coverage against variants, and elevate overall vaccine efficacy. These next-generation mRNA-based COVID-19 vaccines utilize enhanced mRNA engineering and delivery methods, offering more extensive and lasting defense against current and emerging SARS-CoV-2 variants, while also improving safety, stability, and ease of storage, alongside facilitating rapid adaptation to viral evolution. As an illustration, in June 2025, Moderna Inc., a US-based biotechnology company, unveiled mNEXSPIKE, its next-generation COVID-19 vaccine, engineered to bolster defense against prevalent and new SARS-CoV-2 variants. This vaccine features an updated spike protein antigen that better corresponds to recent variants, seeking to provide superior immune durability and effectiveness, thereby aiding continuous COVID-19 prevention initiatives and subsequent booster approaches.
Who Are The Prominent Organizations Shaping The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.
Read the full messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report here:
Which Region Is Anticipated To See The Fastest Growth In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?
North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33215&type=smp
Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company
Mrna Cancer Vaccines And Therapeutics Market Report 2026
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model